Sai Life Sciences has debuted at Rs 660.00 on the BSE, up by 111 points or 20.22% from its issue price of Rs 549.00.
The scrip is currently trading at Rs 705.85, up by 156.85 points or 28.57% from its issue price.
It has touched a high and low of Rs 724.00 and Rs 651.20 respectively. So far 21.95 lakh shares were traded on the counter.
The offering, which was open for subscription between December 11, 2024 and December 13, 2024 was subscribed over 30.90 times. The issue price was fixed at Rs 549.00 per share i.e. at upper end of price band of Rs 522-549 apiece.
Sai Life Sciences is a pure play fully-integrated, innovator-focused, contract research, development and manufacturing organization. It provides end-to-end services across the drug discovery, development and manufacturing value chain for small molecule new chemical entities to global pharmaceutical innovators companies and biotechnology firms.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: